New hope for Alzheimer's in down syndrome: drug trial launches
NCT ID NCT07636811
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 4 times
Summary
This study tests a drug called mivelsiran in 58 adults with Down syndrome who have early-stage Alzheimer's. Participants receive either the drug or a placebo via injection into the spine every few months for two years. The goal is to see if the drug can reduce brain changes linked to Alzheimer's and slow the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mivelsiran (ALN-APP)
- What this could lead to
- If successful, this could point toward a treatment that slows or stops Alzheimer's progression in people with Down syndrome.
- What could go wrong
- This is an early Phase 2 trial with only 58 participants, so results may not apply to everyone. The drug is injected into the spine, which carries risks like infection or headache.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DOWN SYNDROME-ASSOCIATED ALZHEIMER'S DISEASE (DS-AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Study Site
RECRUITINGMaitland, Florida, 32751, United States
-
Clinical Study Site
RECRUITINGNaples, Florida, 34105, United States